PAVmed Inc. operates as a medical device company in the United States. The company’s product pipeline includes NextFlo, a disposable infusion pump; PortIO, a long-term implantable vascular access device; Caldus, a disposable tissue ablation device; CarpX, a percutaneous device to treat carpal tunnel syndrome; and NextCath, a self-anchoring short-term catheter. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is headquartered in New York, New York.
Type
Public
HQ
Queens, US
Founded
2014
Size (employees)
2 (est)
Website
pavmed.com
PAVmed was founded in 2014 and is headquartered in Queens, US

PAVmed Office Locations

PAVmed has an office in Queens
Queens, US (HQ)
4600 251 1 Grand Central Parkway Service Road

PAVmed Data and Metrics

PAVmed Financial Metrics

USD

Net income (Q1, 2017)

(4.3 m)

EBIT (Q1, 2017)

(2.2 m)

Market capitalization (20-Jul-2017)

50.8 m

Closing share price (20-Jul-2017)

4.1

Cash (31-Mar-2017)

905.7 k
PAVmed's current market capitalization is $50.8 m.
USDFY, 2016

R&D expense

607 k

General and administrative expense

1.1 m

Operating expense total

1.7 m

Net Income

(5.7 m)
USDQ2, 2016Q3, 2016Q1, 2017

R&D expense

656.7 k

General and administrative expense

1.5 m

Operating expense total

2.2 m

EBIT

(2.2 m)

Pre tax profit

(4.3 m)

Net Income

(1.3 m)(1.9 m)(4.3 m)
USDFY, 2016

Cash

585.7 k

Accounts Receivable

82.3 k

Inventories

155.5 k

Current Assets

741.2 k

Total Assets

870.4 k

Accounts Payable

949.4 k

Current Liabilities

1.2 m

Additional Paid-in Capital

7.4 m

Retained Earnings

(7.7 m)
USDQ2, 2016Q3, 2016Q1, 2017

Cash

3 m1.8 m905.7 k

Current Assets

3.1 m2 m1.1 m

Total Assets

3.2 m2 m1.1 m

Accounts Payable

216.1 k609.9 k934.2 k

Current Liabilities

403.3 k842.2 k

Additional Paid-in Capital

6.8 m7.1 m7.6 m

Retained Earnings

(4.1 m)(6 m)(12 m)

Total Equity

2.7 m1.1 m(4.3 m)

Financial Leverage

1.1 x1.7 x-0.3 x
USDFY, 2016

Net Income

(5.7 m)

Depreciation and Amortization

3.8 k

Inventories

(146.7 k)

Accounts Payable

877.6 k

Cash From Operating Activities

(4.5 m)

Purchases of PP&E

(21.8 k)

Cash From Investing Activities

(21.8 k)

Cash From Financing Activities

4.3 m
USDQ2, 2016Q3, 2016Q1, 2017

Net Income

(1.3 m)(1.9 m)(4.3 m)

Accounts Payable

216.1 k609.9 k934.2 k
Y, 2017

Financial Leverage

-0.3 x

PAVmed Market Value History

PAVmed Online and Social Media Presence

PAVmed News and Updates

PAVmed Company Life and Culture

You may also be interested in